Concord Biotech has fastened the price band for its maiden supply on the market at ₹705-741 per fairness share with a face worth of ₹1.
The preliminary public providing (IPO) of the corporate will open on Friday (August 4) for subscription and can shut on Tuesday (August 8). Investors can bid for a minimal of 20 shares and in multiples of 20 shares thereafter. The IPO is solely a proposal on the market up to 20.92 million shares by Helix Investment Holdings Pte. Ltd. The supply additionally consists of a reservation for a subscription by eligible staff.
The supply on the market will fetch ₹1,475.26 crore at the decrease finish and ₹1,550.59 crore at the higher finish of the price band.
